Acute d-amphetamine (d-Amph) administration to rats leads to the release of arachidonic acid (AA,) as a second messenger following indirect agonism at dopamine D 2 -like receptors in the brain. We hypothesized that chronically administered d-Amph in rats also would alter brain AA metabolism and signalling. To test this, adult male rats were injected i.p. daily for 2 wk with saline or 2.5 mg/kg d-Amph. After a 1-d washout, the unanaesthetized rats were injected acutely with i.v. saline, 1 mg/kg quinpirole (a D 2 -like receptor agonist) or 5.0 mg/kg SKF-38393 (a D 1 -like receptor agonist), followed by i.v.
Introduction
when given acutely to experimental animals induces hyperactivity and stereotypies (Robinson and Becker, 1986) , and in humans chronic amphetamine can ameliorate symptoms of attention deficit hyperactivity disorder (Lopez et al., 2004) . Chronic d-Amph can also lead to addiction (Di Chiara et al., 2004 ; White and Kalivas, 1998) , while withdrawal from the drug can result in depression and other behavioural symptoms (Lago and Kosten, 1994) .
The central action of d-Amph has been ascribed to its ability to modify dopamine (DA) neurotransmission (Butcher et al., 1988 ; Laruelle et al., 1997) . Acute d-Amph increases brain extracellular DA by changing the direction of DA transport by the presynaptic DA reuptake transporter (DAT) (Jones et al., 1998 ; Segal et al., 1980) , by stimulating DA synthesis (Uretsky and Snodgrass, 1977) , and by inhibiting brain monoamine oxidase activity (Miller et al., 1980) . Acute d-Amph can also increase extracellular norepinephrine by facilitated exchange-diffusion at the presynaptic norepinephrine reuptake transporter (Berridge and Stalnaker, 2002 ; Han and Gu, 2006) .
In animals, repeated exposure to d-Amph exacerbates hyperactivity and stereotypy, which can remain for days to months after discontinuation of drug (Paulson et al., 1991 ; Robinson and Becker, 1986) . In rats and monkeys, chronic d-Amph has been reported to reduce striatal extracellular DA as well as the densities of D 2 -like (D 2 , D 3 , D 4 ) receptors, specifically D 2 and D 3 receptors. When rats were injected daily with d-Amph for 7-16 d, striatal DA at 12 h to 7 d after the last injection was reduced by 25-50 % compared to controls (Lillrank et al., 1991 ; Weiss et al., 1997) , and forebrain D 3 receptor density also was reduced (Chiang et al., 2003) . Following daily administration of 2-10 mg/kg d-Amph for 2-3 wk, striatal D 2 -like receptor density was reduced by 20-26 % in monkeys (Ginovart et al., 1999) and by 22 % in rats (Robertson, 1986) . Repeated daily administration of d-Amph (3-5 mg/kg) decreased (Mintz et al., 1994) , increased (Lu and Wolf, 1997) or did not affect (Kula and Baldessarini, 1991) DAT density or function in rat caudate-putamen. The ability to image brain signal transduction in vivo could provide information about neurotransmission following chronic d-Amph which is unavailable by current imaging modalities (Neve et al., 2004 ; Rapoport, 1995) .
To begin to do this, we have developed an in-vivo imaging method to quantify regional brain arachidonic acid (AA, signalling and metabolism at rest and during drug activation of receptors coupled to Ca 2+ -dependent AA-selective cytoplasmic phospholipase A 2 (cPLA 2 ) (Rapoport, 2001 ; Robinson et al., 1992) . We use quantitative autoradiography to measure coefficients of incorporation k* (brain radioactivity/integrated plasma radioactivity) of unesterified plasma AA into brain, following the i.v. injection of radiolabelled AA (Bhattacharjee et al., 2005 ; DeGeorge et al., 1991 ; Hayakawa et al., 2001) . The amount of AA metabolized following PLA 2 activation will be rapidly replaced by radiolabelled AA in plasma. Thus, k* is proportional to the rate of brain AA metabolic loss, as AA is a nutritionally essential polyunsaturated fatty acid that cannot be synthesized de novo in vertebrate tissue nor significantly elongated in brain from its shorter chain n-6 precursors (DeMar et al., 2006 ; Rapoport et al., 2001) . The exact rate of AA consumption equals J in , the product of k* and the unesterified plasma AA concentration. k* and J in explicitly represent brain AA metabolic loss because they are independent of changes in regional cerebral blood flow (Chang et al., 1997 ; Robinson et al., 1992) .
Using our method, we reported that acute administration to unanaesthetized rats of quinpirole, a D 2 -like receptor agonist, increased k* for AA in brain regions having high D 2 -like receptor densities, and that the increases could be blocked by pre-treatment with butaclamol, a preferential D 2 -like receptor antagonist (Bhattacharjee et al., 2005 ; Hayakawa et al., 2001 ; Levant et al., 1992) . Administration of the D 1 -like receptor agonist, SKF-38393 did not change k* significantly (Bhattacharjee et al., 2005) . These results are consistent with evidence that D 2 -like receptors can be coupled via a G-protein to cPLA 2 (Clark et al., 1991 ; Nilsson et al., 1998 ; Vial and Piomelli, 1995) , which is localized mainly on post-synaptic excitatory dendrites and upon activation selectively releases AA (20 : 4n-6) from the stereospecifically number-2 position of membrane phospholipids (Clark et al., 1991 ; Nilsson et al., 1998 ; Ong et al., 1999 ; Pardue et al., 2003 ; Vial and Piomelli, 1995) . D 1 -like receptors are not so coupled in the intact rat brain (Bhattacharjee et al., 2005 ; Cooper et al., 2003) , but can become coupled following a chronic lesion of the substantia nigra, the source of DA innervation to the striatum (Cai et al., 2002 ; Hayakawa et al., 2001) . We also reported that acute d-Amph increased k* for AA in a dosedependent manner at doses of 0.5 mg/kg and 2.5 mg/ kg i.p. (Bhattacharjee et al., 2006) , and that the increases could be entirely blocked by pretreatment with raclopride, a selective D 2 -like receptor antagonist (Bhattacharjee et al., 2006) , a finding that reveals coupling via D 2 -selective agonism.
The contribution of the PLA 2 pathway to effects of chronic d-Amph has not been investigated. In the present study, we hypothesized that chronic d-Amph will depress AA signalling. We used our autoradiographic method to test this hypothesis and quantify the baseline brain AA incorporation coefficient k* in rats 1 d after a 2-wk treatment with d-Amph (2.5 mg/ kg i.p. daily), when the drug had washed out from brain (amphetamine half-lives in rat plasma and brain are 1-2 h ; Hutchaleelaha et al., 1994) . We also wanted to see if AA signalling responses to acute quinpirole and SKF-38393 were altered in animals given chronic d-Amph compared with chronic saline (controls).
Materials and methods

Chemicals and drugs
[1-
14 C]AA in ethanol (50 mCi/mmol, 99 % pure) was purchased from Moravek Biochemicals (Brea, CA, USA). (x)Quinpirole (LY-171,555) and R-(+)SKF-38393 were obtained from Research Biochemicals International (Natick, MA, USA). d-Amph sulfate, Hepes, and fatty acid-free bovine serum albumin were purchased from Sigma Chemical Company (St Louis, MO, USA). Sodium pentobarbital was purchased from Richmond Veterinary Supply Company (Richmond, VA, USA). SKF-38393 was dissolved in vehicle, 77 mM NaCl/10 % propylene glycol. d-Amph and quinpirole were dissolved in 0.9 % saline before injection.
Animals
The study was approved by the National Institute of Child Health and Human Development Animal Care and Use Committee (Protocol 03-012), and was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication 86-23). Male Fischer-CDF rats were obtained from Charles River Laboratories (Wilmington, MA, USA). They were acclimatized for at least 7 d in an animal facility with constant temperature, humidity, and lighting cycle (06:00-18:00 hours), and had ad libitum access to NIH-31 18-4 diet (Zeigler Bros, Gardners, PA, USA) and water. Starting at age 12.7¡0.8 wk, rats were injected i.p. with either 2.5 mg/kg d-Amph sulfate or 1 ml/kg 0.9 % saline once daily for 2 wk.
Arterial and venous catheter placement
One day after the last of the chronic i.p. saline or d-Amph injections, polyethylene catheters (PE 50) (Becton Dickinson, Sparks, MD, USA) filled with heparin (50 IU) in 0.9 % saline were surgically implanted into the right femoral artery and vein after rats were anaesthetized with halothane (1-2.5 % v/v in O 2 ). The incision was infiltrated with 1 % lidocaine hydrochloride and closed with clips. The rat was loosely bound in a fast-setting plaster cast with its upper body free, and the cast was attached to a wooden block. The rat was allowed to recover from anaesthesia in a sound-dampened, temperature-controlled box for 3-4 h to prevent effects of anaesthesia on brain metabolism (Kimes et al., 1985 ; Sokoloff et al., 1977) . Arterial blood pressure, heart rate, and rectal temperature were measured prior to and 11 min after i.v. quinpirole, SKF-38393 or saline.
Radiolabelled AA infusion
Drug doses were chosen on the basis of published studies (Basselin et al., 2005 ; Bhattacharjee et al., 2005 Bhattacharjee et al., , 2006 Hayakawa et al., 2001 ; Mintz et al., 1994 ; Palacios and Wiederhold, 1985 ; Robertson, 1986) . Experiments were divided into two studies performed at different times. In Study 1, rats that had been treated daily with chronic saline or amphetamine for 2 wk were acutely injected after recovering from anaesthesia with 1.0 ml/kg saline i.v. (saline+saline, n=6 ; d-Amph+saline, n=11) or 1 mg/kg quinpirole (saline+quinpirole, n=8 ; d-Amph+quinpirole, n=10). In Study 2, rats that had been treated daily, as in Study 1, were acutely injected with saline i.v. (saline+saline, n=6 ; d-Amph+saline, n=7) or 5.0 mg/kg SKF-38393 (saline+SKF-38393, n=7; d-Amph+SKF-38393, n=8). Exactly 1 min after an acute injection, the rat was infused i.v. with 170 mCi/ kg [1-
14 C]AA in 2 ml of 5 mM Hepes buffer (pH 7.4), containing 50 mg/ml fatty acid free bovine serum albumin. Infusion was done for 5 min at a rate of 400 ml/min, using an infusion pump (Model 22, Harvard Apparatus, Natick, MA, USA). A total of 13 timed arterial aliquots (70-100 ml) were collected from the start of infusion at 0, 0.2, 0.35, 0.75, 1.5, 3.0, 4.0, 4.9, 5.5, 6.5, 7.5, 10.0, and 19.0 min. The rat was killed at 20 min with sodium pentobarbital (60 mg/kg i.v.). Its brain was removed, quickly frozen in 2-methylbutane at x40 xC, and stored at x80 xC until sectioning. Plasma samples were obtained by centrifuging the arterial blood and were stored at x80 xC.
Radiolabelled unesterified AA in plasma
Arterial plasma was extracted with 3 ml chloroform/ methanol (2 : 1 v/v) and 1.5 ml 0.1 M KCl (Folch et al., 1957) . Liquid scintillation counting, using the Liquid Scintillation Analyzer (Model 2200CA, Packard Instruments, Downer's Grove, IL, USA), was used to determine labelled unesterified AA concentration in 100 ml of the lower organic phase.
Unesterified fatty-acid concentrations were determined in y100 ml of the arterial plasma collected after the rats had recovered from anaesthesia, but before any acute saline or drug. Total lipids were extracted (Folch et al., 1957) and separated by thin layer chromatography on silica gel 60 plates (Whatman, Clifton, NJ, USA), using the solvent system heptane : diethylether : glacial acetic acid (60 : 40 : 3 by vol) (Skipski et al., 1968) . Fatty acids were scraped from the plate and methylated with 1 % H 2 SO 4 in anhydrous methanol (by vol) for 3 h at 70 xC (Makrides et al., 1994) , then quantified by gas chromatography using heptadecanoic acid (17 : 0) as an internal standard.
Autoradiography
Frozen brains were cut in 20-mm-thick coronal sections in a cryostat at 20 xC (Hacker Instruments, Fairfield, NJ, USA). At 100-mm intervals, sets of three adjacent slices were compiled on 22r44 mm coverslips and dried for at least 5 min on a 55 xC hot plate. The coverslips, together with calibrated [
14 C]methylmethacrylate standards (Amersham, Arlington Heights, IL, USA), were exposed for 5 wk to autoradiographic film (Ektascan C/RA, Eastman Kodak Company, Rochester, NY, USA), and the film was developed following the manufacturer's instructions. Radioactivity in 62 anatomically identified brain regions Chronic amphetamine reduces brain AA signalling 959 by guest on October 7, 2016 http://ijnp.oxfordjournals.org/ (Paxinos and Watson, 1987) was measured bilaterally six times by quantitative densitometry, using the public domain Image 1.62 Analysis NIH Program created by Wayne Rasband (National Institutes of Health, Bethesda, MD). Regional brain incorporation coefficients k* of AA were calculated as follows (Bhattacharjee et al., 2005 ; DeGeorge et al., 1989 DeGeorge et al., , 1991 :
k* is in units of ml/s per g wet weight (specific gravity of brain approximates 1) ; c* brain (20 min) nCi/g is brain radioactivity at 20 min after the onset of infusion as determined by densitometry ; c* plasma nCi/ml is plasma AA radioactivity as determined by scintillation counting ; t min is time after onset of [1-14 C]AA infusion.
Statistical analysis
A two-way ANOVA was used to compare main effects (chronic d-Amph vs. chronic saline ; acute quinpirole vs. acute saline ; acute SKF-38393 vs. acute saline) as well as interactions in rats administered either chronic saline or d-Amph and 1 d later acutely challenged with saline, quinpirole or SKF-38393 (SAS 9.1 ; SAS Institute, Cary, NC, USA). At regions in which chronic d-Amphracute quinpirole or acute SKF-38393 interactions were statistically insignificant, probabilities of main effects of chronic and acute treatment were reported separately. At the regions where interactions were statistically significant, these probabilities were not calculated because they cannot be interpreted with certainty (Tabachnick, 2001) . Instead, unpaired t tests were used to evaluate individual significant differences between means. Data are presented as means¡S.D., with statistical significance taken as pf0.05.
Results
Physiological parameters and plasma radioactivity
As shown in Table 1 , there was no significant difference between rats chronically injected with d-Amph (column 4) or saline (column 1) with regard to rectal temperature, heart rate, or arterial blood pressure. As reported (Bhattacharjee et al., 2005 ; Chen et al., 1988) , acute quinpirole significantly increased arterial blood pressure in the chronic saline-treated and d-Amph-treated rats. Acute quinpirole and SKF-38393 produced obvious hyperactivity, stereotyped sniffing and repetitive head movements, but we did not quantify these behaviours. Body weight did not differ between rats chronically treated with d-Amph compared with saline (data not shown).
The mean integral of radioactivity in the plasma organic fraction (nCirs)/ml, the input function in equation (1) 
Plasma concentrations of unlabelled unesterified fatty acids
As illustrated in Table 2 , there was no statistically significant difference in the mean plasma concentration of unesterified palmitate, stearate, arachidonate or docosahexaenoate between chronic d-Amphtreated and chronic saline-treated rats. (Paxinos and Watson, 1987) . Abbreviations : PFr ctx, prefrontal cortex ; Mot ctx, motor cortex ; Som ctx, somatosensory cortex ; CPU, caudate-putamen ; Vis ctx, visual cortex ; MGN, medial geniculate nucleus ; Aud ctx, auditory cortex. nu, Nucleus ; lat., lateral ; med., medial ; sup., superior ; coll., colliculus ; teg., tegmental ; n.s., not significant. Each region of interest was measured in sextuplicate in each rat. Statistical analysis was done using two-way ANOVA. k*=(ml/s per g)r10 x4 . Values are mean¡S.D. of k*.
d-Amph widely reduced baseline values of k* and acute quinpirole increased k* in both chronic saline-treated and d-Amph-treated rats
In Study 1, mean values of k* were determined in 62 brain regions in rats given chronic saline or d-Amph, followed by acute saline or quinpirole (Table 3) . A two-way ANOVA showed no statistically significant interaction between chronic d-Amph and acute quinpirole in any of the 62 regions, suggesting that chronic d-Amph did not alter acute quinpirole's response. A statistically significant negative main effect on k* of chronic d-Amph compared with chronic saline was evident in 60 brain regions (Figure 2c ). In these regions, chronic d-Amph reduced k* by 8-27 %. Acute quinpirole had a significant positive main effect on k* in 30 brain regions, but this increment was not altered by chronic d-Amph. Affected areas included frontal, motor, somatosensory, and part of the auditory cortex, caudate-putamen, globus pallidus, ventral pallidum, thalamic and subthalamic nuclei, superior colliculus and cerebellar grey matter (Figure 2b, d) . In affected regions, quinpirole increased k* by 20-36 % in rats chronically administered There was no significant difference in incremental k* between panels (b) and (d). List of regions : Acb, nucleus accumbens ; AM, anteromedial thalamic nucleus ; Aud, auditory cortex ; AV, anteroventral thalamic nucleus ; CbG, cerebellar grey matter ; CbW, cerebellar white matter ; Cpu, caudate putamen ; DLG, dorsal lateral geniculate nucleus ; EP, entopeduncular nucleus ; Fr, frontal cortex ; GP, globus pallidus ; HB, habenular complex ; HIP, hippocampus ; HYP, hypothalamus ; IC, inferior colliculus ; ICj, Island of Callaja ; iam, interanteromedial thalamic nucleus ; MM, mamillary nucleus ; mG, medial geniculate nucleus ; MolCbG, molecular layer of cerebellar grey matter ; Mot, motor cortex ; OT, olfactory tubercle ; PF, prefrontal cortex ; R, red nucleus ; SNc, substantia nigra ; S, septum ; SS, somatosensory cortex ; SCp, deep layer of superior colliculus ; SCs, superficial layer of superior colliculus ; Sth, subthalamic nucleus ; Vis, visual cortex ; VP, ventral pallidus ; vpm, venteroposterior medial nucleus. saline and by 8-24 % in rats chronically administered d-Amph.
Chronic d-Amph widely reduced k* and SKF-38393 had minimal effects on k*
In Study 2, a two-way ANOVA indicated statistically insignificant interactions between chronic d-Amph and acute SKF-38393 in 58 of the 62 brain regions (see Appendix Table 1 , available in the online version of the paper). d-Amph compared with saline reduced k* in 21 of these regions by 9-29 %. Statistically significant interactions between chronic d-Amph and acute SKF-38393 were found in four of the 62 regions. t tests showed that acute SKF-38393 decreased k* in three of them in chronic saline-treated rats [auditory cortex layer IV (12 %), habenular medial nucleus (18 %), and thalamic venteroposterior medial nucleus (VPM) (25 %)].
In the regions with statistically significant d-Amphr acute SKF-38393 interactions, t tests showed that chronic d-Amph compared with chronic saline decreased k* in auditory cortex layer IV (27 %) and the habenular medial nucleus (22 %). Thus, chronic d-Amph decreased k* in 23 (21+2) of the 62 brain regions in Study 2.
Discussion
Chronic d-Amph (2.5 mg/kg i.p. daily for 2 wk followed by a 1-d washout) had a significant negative main effect on k* for AA in 60 out of 62 brain regions in the study involving quinpirole, and in 23 regions in the study involving SKF-38393. Acute quinpirole (1.0 mg/kg i.v.), a D 2 -like receptor agonist had a positive main effect on k* in 30 regions. Acute SKF-38393, a D 1 -like receptor agonist had no significant main effect on k* in any region. All interactions between chronic d-Amph and acute quinpirole were statistically insignificant, whereas four interactions between chronic d-Amph and acute SKF-38393 were statistically significant at p<0.05 (four might be expected by chance).
We have demonstrated widespread baseline decrements in k* produced by chronic d-Amph, which was presumed as an a-priori hypothesis of predicting decrement of AA signalling by the PLA 2 pathway. Thus, chronic d-Amph mediated decrease in k* responses which are opposite in direction to reported increments caused by acute d-Amph at i.p. doses of 0.5 and 2.5 mg/kg (Bhattacharjee et al., 2006) . Acute d-Amph is thought to increase k* by increasing extracellular DA, thereby activating post-synaptic D 2 -like receptors coupled to cPLA 2 (the increments can be prevented by pretreatment with the D 2 /D 3 receptor antagonist, raclopride) (Bhattacharjee et al., 2005 (Bhattacharjee et al., , 2006 Nilsson et al., 1998 ; Vial and Piomelli, 1995) . The baseline decreases in k* following chronic d-Amph thus probably reflect neuroplastic brain changes. For example, there is a 25-50 % reduction in the striatal DA concentration (Lillrank et al., 1991 ; Weiss et al., 1997) , and decreased densities of striatal and forebrain D 2 and D 3 receptors (Chiang et al., 2003 ; Robertson, 1986) following chronic d-Amph in rats. Whereas acute d-Amph elevated expression of the transcription factors c-fos, fos-B, fra-1, zif 268, jun-B and c-jun in rat brain, chronic d-Amph did not do so or did so to a lesser extent (Persico et al., 1993) .
Quinpirole had a widespread positive main effect on k* in both chronic saline and d-Amph pretreated rats, affecting neocortical areas, basal ganglion, thalamic and subthalamic nuclei (Figure 2 ). Many of these regions have high D 2 -like receptor densities (Levant et al., 1992 ; Levey et al., 1993) and belong to basal ganglia-thalamocortical and limbic circuits involving dopaminergic and glutamatergic neurotransmission (Alexander and Crutcher, 1990 ; Jones, 2002) . Increments in k* following acute quinpirole can be prevented by pretreatment with a preferential D 2 -like receptor antagonist, butaclamol, and are considered to represent D 2 -like receptor activation of cPLA 2 (Bhattacharjee et al., 2005 ; Hayakawa et al., 2001 ). Because chronic d-Amph or saline did not change the plasma concentration of unesterified AA, these k* increments correspond to increments in J in and represent increased loss of the unesterified AA locally released by PLA 2 following drug administration (see Introduction) (Basselin et al., 2006 (Basselin et al., , 2007 DeMar et al., 2006) .
Despite the reported reductions in D 2 and D 3 receptor density in rat brain following d-Amph (see above), the quinpirole-induced positive k* responses did not differ significantly between chronic d-Amphtreated and chronic saline-treated rats, as chronic d-Amph-quinpirole interactions were statistically insignificant. This lack of effect may have been due to quinpirole acting at D 4 or serotonin 5-HT 2B receptors (Levant et al., 1992 ; Millan et al., 2002) , or to up-regulated coupling between cPLA 2 and D 2 or D 3 receptors in the chronic d-Amph-treated rats (Vial and Piomelli, 1995) .
SKF-38393 did not significantly affect k* for AA except in four regions, and these changes can be ascribed to chance, consistent with evidence that D 1 -like receptors are not coupled to AA signalling and PLA 2 activation in normal brain (Bhattacharjee et Cooper et al., 2003 ; Hayakawa et al., 2001) . Clearly d-Amph did not change this lack of coupling, but it can became coupled in chronic substantia nigra-lesioned brains (Hayakawa et al., 2001) . Striatal D 1 -like receptor number has been reported to be unchanged (Barnett et al., 1987 ; Bonhomme et al., 1995) or reduced (Tomic et al., 1997) following chronic d-Amph in rats.
The baseline regional cerebral metabolic rate for glucose (rCMR glc ), a measure of energy consumption at small axonal terminals (Sokoloff, 1999) , was reported not to be altered in comparison to control in any of 39 brain regions at 5-7 h following 2 wk of daily 5 mg/kg amphetamine (Orzi et al., 1983) . In another study, 2 d following 2 wk of daily 5 mg/kg d-Amph, rCMR glc was increased in one of 36 regions examined, within expectation by chance (Huang et al., 1997) . Thus, the widespread depression of baseline k* for AA following 2.5 mg/kg daily d-Amph in our study (Figure 2 ) is very distinct from previous studies using rCMR glc measurements.
Humans as well as rats, after withdrawal from chronic stimulants, often show depressive behaviours that can be ameliorated with antidepressants (Caldecott-Hazard et al., 1988 ; Lago and Kosten, 1994 ; Lynch and Leonard, 1978) . The reduced values of k* that we found 1 d after chronic d-Amph may be related to such depressive behaviour. In contrast, baseline elevations in k* and J in for AA, and increase in brain cPLA 2 activity have been reported in rats that have been chronically administered a daily nonconvulsant dose of N-methyl-D-aspartate (Lee et al., 2008 ; Rao et al., 2007) . In view of these observations, it is likely that the reduced values of k* and J in following chronic d-Amph are accompanied by decreased brain cPLA 2 activity, AA turnover and conversion of AA to eicosanoid products, by down-regulation of the brain AA cascade (Fitzpatrick and Soberman, 2001) . This cascade also is down-regulated in awake rats by chronic administration of lithium and other drugs that are effective against the mania of bipolar disorder (Rapoport and Bosetti, 2002) . It also would be of interest to use positron emission tomography (Esposito et al., 2007 ; Giovacchini et al., 2004 ) to see if k* for AA were depressed in human abusers of d-Amph or of other stimulants following drug withdrawal (Ginovart et al., 1999) .
In summary, 2 wk of daily 2.5 mg/kg i.p. d-Amph, followed by a 1-d washout, reduced baseline incorporation coefficients, k* for AA into the brain of unanaesthetized rats. The reductions were unaccompanied by significantly altered responses to either a D 1 -like or D 2 -like receptor agonist. They suggest that chronic d-Amph down-regulates baseline brain AA consumption and signalling due to neuroplastic effects.
Note
Supplementary material accompanies this paper on the Journal's website (http://journals.cambridge.org).
